Whether the purpose is to find patients with specific mutations, monitoring therapeutic effect, measure residual disease or detect relapses, SAGA has developed ultrasensitive products for liquid and tissue biopsy testing.

SAGAsafe® and SAGAsign® are multipurpose and can be used across a patient’s journey, to monitor response to therapy, measure the change in tumor size, detect minimal residual disease, and aid in predicting prognosis and identifying targetable aberrations.


Detects mutations, 100-fold improved compared to competing methods

Read More


Monitoring tumor burden, residual disease, and response to therapy

Read More


Panel-based NGS solution, in development

Read More